Last reviewed · How we verify
sphingosine kinase-2 inhibitor ABC294640
sphingosine kinase-2 inhibitor ABC294640 is a Small molecule drug developed by RedHill Biopharma Limited. It is currently in Phase 1 development. Also known as: SK2 inhibitor ABC294640.
At a glance
| Generic name | sphingosine kinase-2 inhibitor ABC294640 |
|---|---|
| Also known as | SK2 inhibitor ABC294640 |
| Sponsor | RedHill Biopharma Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia (PHASE2, PHASE3)
- A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma (PHASE2)
- A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma (PHASE2)
- Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)
- Addition of Opaganib to Androgen Antagonists in Patients With mCRPC (PHASE2)
- A Study of Opaganib in Coronavirus Disease 2019 Pneumonia (PHASE2)
- ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma (PHASE1, PHASE2)
- Compassionate Use of Opaganib in Patients With Coronavirus Disease 2019 (COVID-19)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sphingosine kinase-2 inhibitor ABC294640 CI brief — competitive landscape report
- sphingosine kinase-2 inhibitor ABC294640 updates RSS · CI watch RSS
- RedHill Biopharma Limited portfolio CI
Frequently asked questions about sphingosine kinase-2 inhibitor ABC294640
What is sphingosine kinase-2 inhibitor ABC294640?
sphingosine kinase-2 inhibitor ABC294640 is a Small molecule drug developed by RedHill Biopharma Limited.
Who makes sphingosine kinase-2 inhibitor ABC294640?
sphingosine kinase-2 inhibitor ABC294640 is developed by RedHill Biopharma Limited (see full RedHill Biopharma Limited pipeline at /company/redhill-biopharma-limited).
Is sphingosine kinase-2 inhibitor ABC294640 also known as anything else?
sphingosine kinase-2 inhibitor ABC294640 is also known as SK2 inhibitor ABC294640.
What development phase is sphingosine kinase-2 inhibitor ABC294640 in?
sphingosine kinase-2 inhibitor ABC294640 is in Phase 1.
Related
- Manufacturer: RedHill Biopharma Limited — full pipeline
- Also known as: SK2 inhibitor ABC294640